Elyssa Sliheet

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy

J. Nemunaitis, D. Willoughby, L. Stanbery, 2021, Cancer Gene Therapy.